Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 6/20 | 0.56 |
| ▸ | STS | P08842 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.50 |
| ▸ | MMP1 | P03956 | 3/20 | 0.46 |
| ▸ | MMP3 | P08254 | 3/20 | 0.46 |
| ▸ | MMP7 | P09237 | 3/20 | 0.46 |
| ▸ | MMP9 | P14780 | 3/20 | 0.46 |
| ▸ | MMP8 | P22894 | 3/20 | 0.46 |
| ▸ | MMP2 | P08253 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20135307 | 1.00 | MMP13 (0.56) | MMP13STSKMT2AMEN1GPR119 | |
| SCHEMBL24362392 | 0.89 | MMP13 (0.48) | MMP13STSKMT2AMEN1GPR119 | |
| SCHEMBL29768932 | 0.85 | MMP13 (0.46) | MMP13STSKMT2AMEN1GPR119 | |
| SCHEMBL29768871 | 0.85 | MMP13 (0.45) | MMP13STSKMT2AMEN1GPR119 | |
| SCHEMBL20135393 | 0.84 | ALDH1A1 (0.44) | MMP13KMT2AMEN1ALDH1A1 | |
| SCHEMBL28909554 | 0.84 | TGFBR1 (0.47) | MMP13STSGPR119MMP1 | |
| SCHEMBL28909557 | 0.84 | TGFBR1 (0.47) | MMP13STSGPR119MMP1 | |
| SCHEMBL29768875 | 0.83 | MMP13 (0.44) | MMP13STSKMT2AMEN1GPR119 | |
| SCHEMBL5330597 | 0.81 | LMNA (0.47) | MMP13STSKMT2AMEN1GPR119 | |
| SCHEMBL18314687 | 0.81 | LMNA (0.47) | MMP13STSKMT2AMEN1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112437772-A | Bcl-2 inhibitors | 百济神州有限公司 | 2021-03-02 | — | — | CN | disclosed |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | MMP13 7/4885STS 1401/4885KMT2A 2568/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | MMP13 8/4885STS 1402/4885KMT2A 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.